REPUBLIQUE
ET CANTON
DE GENEVE

Gastroesophageal reflux disease, or GERD, patients taking the ADX10059 compound had 2.5 symptom-free days in the second week of treatment compared with 1.7 symptom-free days in patients taking a placebo, the Geneva-based company said. The therapy was also well tolerated. Addex’s treatment belongs to a class of drugs known as allosteric modulators, which bind to a different part of the cell than other medicines, potentially reducing side effects. The Swiss company has agreements with Merck & Co. and Johnson & Johnson covering the development of such compounds for Parkinson’s disease and schizophrenia. Addex is also developing ADX10059 as a treatment for migraine. The medicine is in the second of three phases of testing required for approval. The Swiss company is talking to several big drugmakers about selling rights to ADX10059, which is expected to move into the third and final phase of testing needed for regulatory approval after a licensing deal, according to Vincent Mutel, CEO of Addex. To learn more about Addex : www.addexpharma.com